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in patients with chronic kidney disease and
hyperkalemia on renin-angiotensin systemTreatment with patiromer decreases aldosterone
inhibitors
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Jinwei Yuan3, Lance Berman3 and Gordon H. Williams4
1Division of Nephrology, Department of Medicine, University of Maryland, Baltimore, Maryland, USA; 2University of Chicago, Chicago,
Illinois, USA; 3Relypsa, Redwood City, California, USA; and 4Brigham and Women’s Hospital/Harvard Medical School, Boston,
Massachusetts, USAElevated serum aldosterone can be vasculotoxic and
facilitate cardiorenal damage. Renin-angiotensin system
inhibitors reduce serum aldosterone levels and/or block
its effects but can cause hyperkalemia. Patiromer,
a nonabsorbed potassium binder, decreases serum
potassium in patients with chronic kidney disease on renin-
angiotensin system inhibitors. Here we examined the effect
of patiromer treatment on serum aldosterone, blood
pressure, and albuminuria in patients with chronic kidney
disease on renin-angiotensin system inhibitors with
hyperkalemia (serum potassium 5.1–6.5 mEq/l). We
analyzed data from the phase 3 OPAL-HK study (4-week
initial treatment phase of 243 patients; 8-week randomized
withdrawal phase of 107 patients). In the treatment phase,
the (mean ± standard error) serum potassium was
decreased concordantly with the serum aldosterone
(L1.99 ± 0.51 ng/dl), systolic/diastolic blood pressure
(L5.64 ± 1.04 mm Hg/L3.84 ± 0.69 mm Hg), and albumin-
to-creatinine ratio (L203.7 ± 54.7 mg/g), all in a statistically
signiﬁcant manner. The change in the plasma renin activity
(L0.44 ± 0.63 mg/l/hr) was not signiﬁcant. In the
withdrawal phase, mean aldosterone levels were sustained
with patiromer (D0.23 ± 1.07 ng/dl) and signiﬁcantly
increased with placebo (D2.78 ± 1.25 ng/dl). Patients on
patiromer had signiﬁcant reductions in mean systolic/
diastolic blood pressure (L6.70 ± 1.59/L2.15 ± 1.06
mm Hg), whereas those on placebo did not (L1.21 ± 1.89
mm Hg/D1.72 ± 1.26 mm Hg). Signiﬁcant changes in
plasma renin activity were found only in the placebo group
(–3.90 ± 1.41 mg/l/hr). Thus, patiromer reduced serum
potassium and aldosterone levels independent of plasma
renin activity in patients with chronic kidney disease and
hyperkalemia on renin-angiotensin system inhibitors.
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B ecause of the increased prevalence of hyperkalemia(HK) in patients with renal dysfunction, novel agentshave recently been developed to reduce serum potas-
sium (sK) levels by binding potassium in the gastrointestinal
tract.1 Although these agents have produced the intended
beneﬁcial effect of reducing potassium levels,2 there may be
added beneﬁts from this form of therapy—a reduction in
aldosterone production.
Higher levels of serum aldosterone are associated with
increased mineralocorticoid receptor stimulation; this ligand-
receptor interaction has been well demonstrated to promote
cardiovascular and renal disease progression in experimental
and clinical studies.3-9 By blocking this interaction, miner-
alocorticoid receptor antagonists have demonstrated beneﬁts
in patients with heart failure and post-acute myocardial
infarction.7 Moreover, blocking the mineralocorticoid recep-
tor is associated with reductions in blood pressure (BP) and
albuminuria,8 suggesting that this type of therapeutic approach
may reduce the rate of renal disease progression. Recent
studies have also suggested that mineralocorticoid receptor
activation may lead to metabolic dysregulation and suscepti-
bility to type 2 diabetes mellitus and atherosclerosis.10-13
Consequently, there is great interest in reducing the
adverse effects of aldosterone, which can be accomplished
with mineralocorticoid receptor antagonists.7,14 Yet, the use of
mineralocorticoid receptor antagonists in patients with renal
dysfunction is associated with a substantial incidence of HK,
which limits their use either alone or combined with
angiotensin-converting enzyme inhibitors or angiotensin re-
ceptor blockers.15-19 For example, in 2009, Khosla et al.20
reported a rate of HK (potassium >5.5 mEq/l) of 34.7% in
patients treated with a mineralocorticoid receptor antagonist
who had a baseline serum potassium level >4.5 mEq/l and a
glomerular ﬁltration rate #45 ml/min per 1.73 m2. This
limitation is a concern, especially in patients with congestive
heart failure, with or without renal dysfunction, in whom theKidney International (2016) 90, 696–704
Table 1 | Baseline demographic and clinical characteristics
Characteristic
Initial
treatment
phase
Overall
(N [ 243)
Randomized withdrawal
phase
Placebo
(N [ 52)
Patiromer
(N [ 55)
Male sex, n (%) 140 (58) 30 (58) 28 (51)
Age, yr, mean  SD 64.2  10.5 65.0  9.1 65.5  9.4
White race, n (%)a 239 (98) 52 (100) 55 (100)
Type 2 diabetes, n (%) 139 (57) 33 (63) 34 (62)
Heart failure, n (%) 102 (42) 22 (42) 27 (49)
NYHA functional class,
n (%)
I 19 (19) 4 (18) 5 (19)
II 66 (65) 14 (64) 18 (67)
III 17 (17) 4 (18) 4 (15)
Myocardial infarction, n (%) 60 (25) 14 (27) 18 (33)
Hypertension, n (%) 236 (97) 50 (96) 54 (98)
Serum potassium, mEq/l,
mean  SDb
5.6  0.5 5.9  0.4 5.9  0.6
Estimated GFR, ml/min per
1.73 m2, n (%)c
Stage 2: 60 to <90 22 (9) 4 (8) 8 (15)
Stage 3A: 45 to <60 49 (20) 11 (21) 11 (20)
Stage 3B: 30 to <45 63 (26) 14 (27) 15 (27)
Stage 4/5: <30 109 (45) 23 (44) 21 (38)
RAASi use, n (%)c 243 (100) 52 (100) 55 (100)
ACE inhibitor 170 (70) 38 (73) 37 (67)
Angiotensin II receptor
blocker
92 (38) 16 (31) 24 (44)
MRA 22 (9) 4 (8) 4 (7)
Renin inhibitor 2 (1) 0 0
Dual RAAS blockaded 41 (17) 6 (12) 10 (18)
Receiving maximal dosee 106 (44) 21 (40) 21 (38)
Non-RAASi diuretic use,
n (%)c
132 (54) 27 (52) 28 (51)
Thiazide 70 (29) 11 (21) 16 (29)
Loop 77 (32) 20 (38) 16 (29)
Serum aldosterone, ng/dl,
mean  SDb
11.86  11.31 11.83  12.40 13.36  12.14
ACE, angiotensin-converting enzyme; GFR, glomerular ﬁltration rate; MRA, mineral-
ocorticoid receptor antagonist; NYHA, New York Heart Association; RAAS, renin-
angiotensin-aldosterone system; RAASi, renin-angiotensin-aldosterone system
inhibitor.
aRace was determined by the investigators.
bThe values in this row refer to baseline values at the start of the study.
cThe values for patiromer and placebo in this row refer to baseline values at the start
of the randomized withdrawal phase.
dDual RAAS blockade refers to any combination of $2 of the following: ACE in-
hibitor, angiotensin II receptor blocker, aldosterone antagonist, or renin inhibitor.
eThe maximal dose was determined according to the judgment of the investigator in
accordance with the local standard of care.
MR Weir et al.: Patiromer decreases aldosterone in CKD patients c l i n i ca l i nves t iga t ioneffects of aldosterone reduction provide the greatest
beneﬁt.5-8
Aldosterone production is not only regulated by the renin-
angiotensin-aldosterone system (RAAS), but also by potas-
sium,5,21,22 which is equally potent in modulating aldosterone
secretion.23-28 Thus, the possibility exists that agents that
lower potassium levels may also reduce aldosterone secretion
and may provide an added beneﬁt beyond potassium reduc-
tion in patients with renal dysfunction.
To test this hypothesis, we performed a prespeciﬁed
exploratory analysis of the OPAL-HK clinical trial in which
patiromer, a novel potassium-binding polymer that uses
calcium rather than sodium as the cation for exchange with
potassium, was shown to decrease potassium levels in patients
with chronic kidney disease (CKD) and HK who were being
treated with a RAAS inhibitor (RAASi).2 Based on the pivotal
OPAL-HK study,2 patiromer was recently approved by the US
Food and Drug Administration for the treatment of HK. The
unique design of the OPAL-HK study allowed us to evaluate
changes in aldosterone, BP, and albuminuria according to
baseline potassium level and in a placebo-controlled fashion
to determine whether there are additional beneﬁcial effects of
patiromer beyond sK reduction.
RESULTS
Patient disposition and demographics
Overall, 243 patients were enrolled in the initial treatment
phase, and 107 patients participated in the randomized
withdrawal phase of the study (55 continued patiromer and
52 switched to placebo). The majority of patients had hy-
pertension, diabetes mellitus, and advanced CKD. The base-
line characteristics of patients in these analyses are shown in
Table 1.
Initial treatment phase
Over the 4-week initial treatment phase, mean  SE serum
aldosterone levels decreased (1.99  0.51 ng/dl, P ¼ 0.0001)
in parallel with decreases in sK (Figure 1). When examined by
baseline sK levels, only patients with moderate to severe HK
had signiﬁcant changes from baseline in mean  SE serum
aldosterone levels at week 4 (mild HK: 0.67  0.80, P ¼ not
signiﬁcant [NS]; moderate to severe HK: 3.32  0.63,
P <0.0001) (Table 2). As previously reported,2 patients with
moderate to severe HK (5.5 to <6.5 mEq/l) at baseline had
greater changes from baseline in sK compared with patients
with mild HK (5.1 to <5.5 mEq/l) at baseline. Patients with
mild HK had a mean decrease in sK from baseline to week 4
of 0.65 (0.05) mEq/l compared with 1.23 (0.04) mEq/l in
patients with moderate to severe HK at baseline; both were
statistically signiﬁcant.
BP decreased over the initial 4-week treatment period in
patients receiving patiromer (Figure 2). Themean SE systolic
BP (SBP) change from baseline in patients with mild HK
was 5.7 (1.6) mm Hg (P ¼ 0.0005) and 5.5 (1.3) mm Hg
(P<0.0001) in patients with moderate to severe HK (Table 2).
Mean diastolic BP (DBP) changed from baseline by3.2 (1.1)Kidney International (2016) 90, 696–704mmHg in patients withmildHK (P¼ 0.003) and by4.5 (0.9)
mm Hg in patients with moderate to severe HK (P < 0.0001)
(Table 2).
In the extended multivariate mixed model for repeated
measures (MMRM) model, decreases in mean  SE aldo-
sterone level were associated with baseline serum aldosterone
levels (P < 0.0001), age 65 years or older (P ¼ 0.04), the
presence of type 2 diabetes mellitus (P ¼ 0.02), and the
absence of heart failure (P ¼ 0.04). There was no signiﬁcant
effect of sex and CKD stage on aldosterone reduction
(Supplementary Table S1). After adjustment for baseline
aldosterone and the previously cited covariates, reduction in697
Figure 1 | Observed mean values of serum aldosterone and potassium over time during the initial treatment phase. The observed mean
values were measured in a central laboratory. Missing central laboratory serum potassium values were imputed from local laboratory data.
c l i n i ca l i nves t iga t i on MR Weir et al.: Patiromer decreases aldosterone in CKD patientsserum aldosterone in the moderate to severe HK group was
still signiﬁcant (P < 0.0001).
In the sensitivity analysis, the observed reduction in
aldosterone concentrations remained signiﬁcant after the data
were adjusted for modiﬁcation of antihypertensive agents
(including RAASi and diuretics) and any use of mineralo-
corticoid receptor antagonist at baseline or throughout the
initial treatment phase (Table 3). There was a low incidence of
change in antihypertensive medications in the initial treat-
ment phase (Supplementary Table S2). Overall, 94% of pa-
tients (228/243) had no change in RAASi use; 92% (224/243)
had no change in non-RAASi, nondiuretic use; and 97% (236/
243) had no change in diuretic use. The reason for RAASi
modiﬁcation included heart failure, hypertension, hypoten-
sion, and HK.
At baseline, patients with mild HK had a mean  SE
serum plasma renin activity (PRA) of 11.15 (1.38) mg/l/hr and
patients with moderate to severe HK had a mean  SE serum
PRA of 8.08 (0.92) mg/l/hr) (P ¼ NS). At week 4 of the initial
treatment phase, there were no statistically signiﬁcant changes
in mean  SE PRA in the total population (0.44  0.63
mg/l/hr) or in patients with mild HK (1.10  0.99 mg/l/hr)
or moderate to severe HK (0.22  0.78 mg/l/hr) (Table 2).
There were decreases in mean  SE albumin-to-creatinine
ratio (ACR) from baseline to week 4 for the overall group
(203.7  54.7 mg/g, P ¼ 0.0003). The mean ACR decreased
signiﬁcantly in both the mild HK group (174.3  87.4
mg/g, P # 0.05) and the moderate to severe HK group
(222.1  69.2 mg/g, P ¼ 0.0015) (Table 2).
In order to explore whether serum aldosterone changes
were associated with increased or decreased potassium, PRA,
SBP, and DBP, we conducted 1-way analysis of variance an-
alyses by aldosterone tertiles at baseline and by tertiles of
aldosterone change from baseline at day 3 (early effect) and at
week 4 (end of the initial treatment phase). There was no
correlation between serum aldosterone tertiles and SBP and
DBP at baseline (P ¼ NS for both groups). SBP decreases
were observed across all serum aldosterone changes from
baseline tertiles at day 3 (P ¼ NS) and week 4 (P ¼ 0.034).698DBP decreases were observed across all tertiles of serum
aldosterone change from baseline at day 3 (P ¼ 0.067) and
week 4 (P ¼ NS) (Tables 4–6). Higher serum aldosterone
levels (tertiles) at baseline were signiﬁcantly associated with
higher mean sK levels (P ¼ 0.025), and greater decreases in
serum aldosterone were signiﬁcantly associated with greater
decreases in sK at day 3 (P ¼ 0.004) but not at week 4
(P ¼ NS). Higher levels of aldosterone were correlated with
higher mean PRA (P ¼ 0.04) at baseline, but the tertiles of
change in aldosterone levels were not associated with changes
in PRA at day 3 and week 4.
Randomized withdrawal phase
At the start of the randomized withdrawal phase, differences
in aldosterone levels between patients randomized to
patiromer or placebo were not statistically signiﬁcant. In
patients continuing on patiromer, the mean  SE serum
aldosterone concentrations did not change substantially from
the start (week 4 of the initial treatment phase) to week 8 of
the randomized withdrawal phase (0.23  1.07), whereas
serum aldosterone concentrations increased in patients
switched to placebo (2.78  1.25, P # 0.03) (Table 7).
From the start of the randomized withdrawal phase to
week 8, patients continuing on patiromer and who completed
the withdrawal phase (N ¼ 45) demonstrated statistically
signiﬁcant reductions in mean  SE SBP (6.70  1.59
mm Hg, P <0.0001) and DBP (2.15  1.06 mm Hg,
P # 0.05). Those who switched to placebo and completed the
initial treatment and withdrawal phases (N ¼ 29) did not
demonstrate statistically signiﬁcant changes in SBP (1.21 
1.89 mm Hg, P ¼ NS) or DBP (þ1.72  1.26 mm Hg,
P ¼ NS) (Table 7). There was a statistically signiﬁcant
decrease in PRA from the start of the randomized withdrawal
phase to week 8 (3.90  1.41 mg/l/hr, P ¼ 0.0067) in pla-
cebo patients; there were no statistically signiﬁcant changes
for those patients continuing on patiromer.
By the end of the randomized withdrawal phase, 94% of
patients in the patiromer group were still receiving RAASi
medication compared with 44% of patients in the placeboKidney International (2016) 90, 696–704
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Kidney International (2016) 90, 696–704group. Fifty-two percent of patients in the placebo group
discontinued RAASi therapy due to their insufﬁcient HK
control while on RAASi therapy. Modiﬁcation of non-RAASi,
nondiuretic, antihypertensive medications occurred in #2%
of patients on patiromer and #8% of those switched to
placebo. Through week 8 of the randomized withdrawal
phase, modiﬁcations in diuretics occurred in #3% of patients
switched to placebo and in no patients continuing patiromer.
Safety
Patiromer adverse events (AEs) have been previously
described.2 Brieﬂy, patiromer was well tolerated with a low rate
of discontinuations due to AEs (6% in the initial treatment
phase and 2% in the randomized withdrawal phase). Overall,
47% of patients in the initial treatment phase had at least 1 AE,
with similar percentages reported in the randomized with-
drawal phase (47% and 50% in the patiromer and placebo
groups, respectively). Serious AEs occurred in 3 patients in the
initial treatment phase, 1 patient on placebo, and no patients on
patiromer in the randomized withdrawal phase. As determined
by the investigator, none of the serious AEs were related to
patiromer. The mean serum magnesium level remained
decreased slightly during both phases; no episodes of serum
magnesium <1.2 mg/dl occurred. Hypokalemia (sK <3.5
mEq/l) was infrequent, occurring in 3%of patients in the initial
treatment phase; in the randomized withdrawal phase, 5% of
patients on patiromer and 2% on placebo met prespeciﬁed
withdrawal criteria for sK <3.8 mEq/l.
DISCUSSION
The current analysis notes that patiromer treatment resulted
in reduced aldosterone levels, decreases in BP, and reductions
in urine albumin excretion. The effect of patiromer on
lowering potassium without delivering sodium through
counterion exchange,2 as well as observing decreases in serum
aldosterone, provides an opportunity to examine the bio-
logical effects of reducing sK and serum aldosterone levels. It
is unlikely that the observed reduction in serum aldosterone
occurred by chance and was unrelated to patiromer’s effect on
sK. Decreases in the magnitude that we observed are unlikely
to occur spontaneously in patients with kidney disease,29,30
suggesting that the observed effect on aldosterone was
driven by patiromer treatment. The effect of patiromer on
aldosterone is further supported by the ﬁndings that subjects
switched to placebo in the randomized withdrawal phase had
increases in aldosterone, whereas those who continued
patiromer therapy maintained the decreased aldosterone
levels achieved in the initial treatment phase. The effect of
patiromer on aldosterone was maintained after adjusting
for age, diabetes, and heart failure, factors that may alter
aldosterone levels and could have affected the results.
Although patiromer and other agents are documented to
reduce potassium levels in individuals with CKD,2,31-34 there
are no previously published reports that demonstrate a
reduction in aldosterone, blood pressure, and albuminuria
with these agents.699
Figure 2 | Effect of patiromer on observed mean values of systolic (a) and diastolic (b) blood pressure over time during the initial
treatment phase.
c l i n i ca l i nves t iga t i on MR Weir et al.: Patiromer decreases aldosterone in CKD patientsAldosterone secretion is primarily controlled by angio-
tensin II, potassium, and adrenocorticotrophic hormone, and
increased levels of any of these will increase aldosterone
production, primarily due to effects on an early step in
aldosterone biosynthesis.21-23,35-37 Changes in potassium
levels modify aldosterone levels, as reported in the current
study, due to the high sensitivity of zona glomerulosa cells to
sK levels.21 For example, administering potassium to normal
subjects in doses so small that sK levels are not measurably
changed can modify aldosterone levels by as much as 25%.25Table 3 | Serum aldosterone and blood pressure adjusted for con
phase
Measure
Mild hyperkalemia
(5.1 to <5.5 mEq/l)
LS mean
change from baseline ± SE P value cha
Serum aldosterone (ng/dl) 1.81  0.74 0.0156
Systolic blood pressure (mm Hg) 5.40  1.84 0.0037
Diastolic blood pressure (mm Hg) 3.34  1.21 0.0064
LS, least squares.
The same mixed-effects, repeated-measures model in Table 2 was used by excluding any
system inhibitor, non–renin-angiotensin-aldosterone system inhibitor, nondiuretic antih
P value for mean change compared with baseline.
700Furthermore, in anephric individuals, there were parallel
changes in potassium and aldosterone in between dialysis
sessions.38 Similarly, in the current study, when patiromer
was stopped, potassium and aldosterone levels rose in parallel;
conversely, aldosterone and potassium levels remained sup-
pressed in patients in whom patiromer was continued.
Although the overall duration of the study was longer than
required for aldosterone to escape from the suppressing
effects of agents that interrupt the RAAS,30 it is possible that
aldosterone levels may not continue to be reduced withcomitant selected antihypertensive use in the initial treatment
Moderate/severe hyperkalemia
(5.5 to <6.5 mEq/l)
Overall
(5.1 to <6.5 mEq/l)
LS mean
nge from baseline ± SE P value
LS mean
change from baseline ± SE P value
3.19  0.58 <0.0001 2.50  0.47 <0.0001
5.57  1.44 0.0001 5.48  1.17 <0.0001
4.67  0.95 <0.0001 4.00  0.77 <0.0001
aldosterone antagonist use and any modiﬁcations of renin-angiotensin-aldosterone
ypertensive medications, or of diuretics.
Kidney International (2016) 90, 696–704
Table 5 | Change from baseline to day 3 (mean ± SD) in clinical and laboratory parameters by the tertile of change from
baseline to day 3 (mean ± SD) in serum aldosteronea
Change from baseline to day 3
First tertile of aldosterone
change to day 3
(L6.74 ± 6.89 ng/dl)
Second tertile of aldosterone
change to day 3
(L0.20 ± 0.55 ng/dl)
Third tertile of aldosterone
change to day 3
(4.45 ± 4.36 ng/dl) P value
N 71 73 71
Potassium (mEq/l) 0.56  0.56 0.37  0.41 0.31  0.43 0.0044
Systolic blood pressure (mm Hg) 4.61  14.76 3.35  15.35 4.24  12.95 0.8651
Diastolic blood pressure (mm Hg) 3.64  8.39 2.87  8.88 0.55  7.20 0.0671
Plasma renin activity (mg/l/hr) 0.26  10.03 2.26  10.44 2.33  7.56 0.0162
aACR was not available on day 3. P value for comparisons among tertiles was based on 1-way ANOVA.
Table 4 | Baseline (mean ± SD) clinical and laboratory parameters by the tertile of baseline (mean ± SD) serum aldosterone
Baseline
First tertile of aldosterone at
baseline (3.49 ± 1.2 ng/dl)
Second tertile of aldosterone at
baseline (8.49 ± 1.74 ng/dl)
Third tertile of aldosterone at
baseline (23.77 ± 12.65 ng/dl) P value
N 81 82 80
Potassium (mEq/l) 5.48  0.40 5.54  0.46 5.67  0.47 0.0246
Systolic blood pressure (mm Hg) 142.03  17.35 141.00  17.17 140.88  16.90 0.8962
Diastolic blood pressure (mm Hg) 78.37  11.59 79.91  10.45 77.90  10.54 0.4691
Plasma renin activity (mg/l/hr) 8.21  11.27 7.57  10.55 12.00  14.01 0.0423
ACR (mg/g) 1308.91  2048.70 888.36  1494.20 783.19  1987.20 0.1672
ACR, albumin-to-creatinine ratio; P value for comparisons among tertiles was based on 1-way ANOVA.
MR Weir et al.: Patiromer decreases aldosterone in CKD patients c l i n i ca l i nves t iga t ionlong-term patiromer treatment. Patiromer is unlikely to exert
direct, systemic effects on aldosterone production or meta-
bolism, BP, or albuminuria because patiromer itself is not
systemically absorbed.39
The combination of lower levels of aldosterone, BP, and sK
with patiromer would be expected to have induced a reactive
increase in PRA23,25; there are at least 3 potential explanations
why this did not occur. First, decrease in aldosterone did not
result in a decrease in extracellular volume. Because assess-
ments of volume status were not conducted in this study, we
have no way of directly assessing this possibility. Second, the
usual reciprocal relationship between RAAS and intravascular
volume was abnormal in the basal state (before patiromer
treatment). Thus, even though extracellular volume might
have decreased during patiromer treatment, it did not modify
PRA levels signiﬁcantly, similar to what is seen in low renin
hypertension.40,41 We have no data to support or refute this
possibility. Third, the regulation of renin release/secretion was
altered in these patients, similar to the hyporenemic-
hypoaldosterone syndrome found in some patients with
chronic renal disease.40,41 This seems the least likelyTable 6 | Change from baseline to week 4 (mean ± SD) in clinica
baseline to week 4 (mean ± SD) in serum aldosterone
Change from baseline to week 4
First tertile of aldosterone
change to week 4
(L11.72 ± 8.83 ng/dl)
Seco
N 71
Potassium (mEq/l) 1.07  0.70
Systolic blood pressure (mm Hg) 7.26  16.66
Diastolic blood pressure (mm Hg) 5.08  11.34
Plasma renin activity (mg/l/hr) 0.91  11.51
ACR (mg/g) 100.96  648.21
ACR, albumin-to-creatinine ratio. P value for comparisons among tertiles was based on
Kidney International (2016) 90, 696–704explanation because renin levels were not decreased at base-
line in this study. In sum, the reason that PRA did not in-
crease is unexplained and requires further study.
Based on the current study, there is no direct evidence to
determine whether reductions in BP and albuminuria were
secondary to reductions in aldosterone levels. Aldosterone
levels were not outside the normal range before patiromer
was given and were still within the normal range after drug
administration. Other studies, however, analyzed animal
models that were placed on an unrestricted sodium diet and
had an increased cardiovascular and renal risk and discovered
that blocking the mineralocorticoid receptor or performing
an adrenalectomy prevented cardiovascular and renal dam-
age.42,43 Moreover, restoring aldosterone levels in the adre-
nalectomized rodents restored the damage.42,43 Thus,
aldosterone levels do not need to be clinically elevated to
induce damage. The potential clinical implications of these
ﬁndings suggest that patiromer may have secondary effects on
aldosterone levels that may result in cardiovascular and renal
beneﬁts. However, these effects of patiromer need to be
formally tested.l and laboratory parameters by the tertile of change from
nd tertile of aldosterone
change to week 4
(L1.39 ± 1.26 ng/dl)
Third tertile of aldosterone
change to week 4
(6.05 ± 5.95 ng/dl) P value
73 71
1.01  0.59 0.93  0.72 0.4413
1.56  17.57 8.41  16.39 0.0342
2.94  10.98 3.63  11.40 0.5026
0.52  7.50 0.51  11.19 0.6865
169.97  817.36 345.41  914.91 0.1733
1-way ANOVA.
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Table 7 | Mean ± SE change in clinical and laboratory parameters from start of the randomized withdrawal phase to weeks
4 and 8 of the randomized withdrawal phase
Measure
Patiromer, N [ 55 Placebo, N [ 52
n Mean ± SE
LS mean change
from start ± SE P value n Mean ± SE
LS mean change
from start ± SE P value
Start
Serum aldosterone (ng/dl) 55 10.52  1.25 — — 52 8.61  1.38 — —
Potassium (mEq/l) 55 4.50  0.06 — — 52 4.45  0.05 — —
Systolic blood pressure (mm Hg) 55 134.80  2.19 — — 52 135  2.51 — —
Diastolic blood pressure (mm Hg) 55 76.48  1.60 — — 52 73.65  1.54 — —
Plasma renin activity (mg/l/hr) 55 8.71  1.59 — — 52 7.90  1.53 — —
ACRa (mg/g) 55 441.70  105.50 — — 50 509.40  124.20 — —
Week 4
Serum aldosterone (ng/dl) 50 11.17  1.62 0.94  1.18 0.4262 45 12.28  2.02 3.37  1.24 0.0078
Potassium (mEq/l) 50 4.55 (0.06) 0.07 (0.06) 0.2621 45 4.95 (0.07) 0.51 (0.07) <0.0001
Systolic blood pressure (mm Hg) 50 131.30  2.25 3.91  2.04 0.0582 45 135.90  2.53 0.76  2.14 0.7216
Diastolic blood pressure (mm Hg) 50 73.88  1.38 2.59  1.20 0.0335 45 76.47  1.62 0.78  1.26 0.5359
Plasma renin activity (mg/l/hr) 50 7.37  1.41 0.61  1.15 0.5956 44 6.34  1.45 1.66  1.21 0.1718
ACRa (mg/g) 49 401.80  115.50 50.38  64.17 0.4345 42 613.50  214.70 70.93  69.33 0.3091
Week 8
Serum aldosterone (ng/dl) 45 10.63  1.14 0.23  1.07 0.8296 29 13.08  2.93 2.78  1.25 0.0278
Potassium (mEq/l) 45 4.52  0.06 0.04  0.07 0.5050 29 4.85  0.08 0.55  0.08 <0.0001
Systolic blood pressure (mm Hg) 45 128.50  1.88 6.70  1.59 <0.0001 29 133.50  2.23 1.21  1.89 0.5234
Diastolic blood pressure (mm Hg) 45 74.98  1.13 2.15  1.06 0.0458 29 77.63  1.98 1.72  1.26 0.1734
Plasma renin activity (mg/l/hr) 44 9.64  1.71 1.71  1.21 0.1624 29 4.99  1.37 3.90  1.41 0.0067
ACRa (mg/g) 45 417.10  115.80 18.85  46.59 0.6870 29 339.80  134.90 88.49  58.04 0.1318
ACR, albumin-to-creatinine ratio; LS, least squares.
The mean changes from the start were estimated using a mixed-effects, repeated-measures model, which included the ﬁxed continuous covariate of start values as well as
ﬁxed categorical covariates of the analysis visit and treatment group and used an unstructured covariance structure.
P value for mean change compared with start of randomized withdrawal phase.
aACR was only collected at monthly visits; the mean change from start was based on an analysis of covariance by adjusting for the start value.
c l i n i ca l i nves t iga t i on MR Weir et al.: Patiromer decreases aldosterone in CKD patientsThere are several limitations to our analyses. The study
was not designed to establish a causal relationship between
aldosterone decrease and decreases in BP or ACR. The initial
treatment phase was not placebo controlled, and the sample
size of the placebo-controlled randomized withdrawal phase
of the study was relatively small (N ¼ 107). Although
infrequent, changes in non-RAASi antihypertensive medi-
cations may also have confounded the observed effects on
BP and ACR despite our attempts to control for these fac-
tors. In the randomized withdrawal phase, discontinuation
of RAASi medications occurred in more than half of the
placebo group, preventing direct between-group statistical
comparisons of BP, ACR, and aldosterone levels with the
patiromer group in whom discontinuations were uncom-
mon (6%). We chose to examine within-group comparisons
for evaluating changes beyond the initial 4 weeks of treat-
ment (continued patiromer treatment) as well as the effects
of patiromer withdrawal (placebo group) rather than
between-group comparisons, which would have been subject
to greater confounding due to differences in RAASi adher-
ence. Because the study population was almost entirely
white, the results may not be generalizable to other groups
that may have differences in RAAS compared with whites.44
The ﬁndings of this study should be interpreted with
caution. Even considering the previously cited factors, the
reduction in aldosterone concentration during the initial
treatment phase is striking as is the persistence of the effect
over the 12 weeks of treatment and the loss of this effect in702patients switched to placebo in the randomized withdrawal
phase. Finally, it is not possible to determine whether the
results observed in this study are equally applicable to all
potassium-lowering agents.
In summary, patiromer treatment in individuals with HK
and CKD lowers potassium and aldosterone levels and is
associated with reductions in BP and albuminuria. Treatment
with patiromer may improve cardiovascular risk beyond that
associated with reduction in potassium levels. This hypothesis
will need formal testing.METHODS
Study design and participants
The study design of theOPAL-HK study was previously described2 as a
sequential, 2-part, placebo-controlled, 12-week phase 3 study evalu-
ating patiromer treatment in 243 patients with CKD andHKonRAASi
medications. Brieﬂy, participants were enrolled in an initial 4-week
treatment phase followed by an 8-week randomized withdrawal
phase. Eligible patients were adults with CKD stage 3 or 4 (estimated
glomerular ﬁltration rate 15 to<60ml/min per 1.73m2) and sK levels
of 5.1 to <6.5 mEq/l at screening based on local laboratory mea-
surement and who were on a stable dose of RAASi medication for at
least 28 days before screening. Patiromer starting doses at the begin-
ning of the initial 4-week treatment phase were based on screening sK
levels (4.2 g twice daily formildHK [5.1 to<5.5mEq/l] and 8.4 g twice
daily for moderate to severe HK [5.5 to <6.5 mEq/l]). The dose was
adjusted according to a prespeciﬁed algorithm2 to maintain sKwithin
the range of 3.8 to<5.1 mEq/l. During this phase, RAASi therapy was
not allowed to be adjusted unless medically necessary, but could beKidney International (2016) 90, 696–704
MR Weir et al.: Patiromer decreases aldosterone in CKD patients c l i n i ca l i nves t iga t iondiscontinued if potassium was $6.5 mEq/l (or $5.1 mEq/l while on
maximum doses of patiromer).
Patients eligible for the 8-week randomized withdrawal phase of
the study had moderate to severe HK ($5.5 mEq/l based on central
laboratory values) at baseline of the initial 4-week treatment
phase and sK between 3.8 and <5.1 mEq/l (normokalemic) at the
end of that phase. Additional eligibility requirements included
receiving both patiromer treatment and RAASi therapy at the end of
the initial 4-week treatment phase. Eligible patients were randomized
(1:1 ratio) to either continue patiromer at the daily dose that they
were receiving at week 4 of the initial treatment phase or to switch to
placebo. Recurrence of HK was managed according to a prespeciﬁed
algorithm as previously described.2 During the ﬁrst 4 weeks of the
8-week withdrawal phase, while the primary endpoint was under
evaluation, recurrent HK (serum Kþ $5.5 mEq/l) was managed
by increasing the dose in the patiromer group at an increment of
8.4 g/day or by decreasing the RAASi dose by 50% in the placebo
group. During the second 4 weeks, after the primary endpoint had
been evaluated, these measures were implemented if the serum
potassium increased to 5.1 mEq/l. At any time, if these measures
were insufﬁcient to control recurrent HK, RAASi medication
in either group had to be withdrawn. Investigators could add or
modify potassium-neutral non-RAASi antihypertensive medications
to control BP during the initial 4-week treatment phase or the
8-week randomized withdrawal phase.
Laboratory assessments conducted at baseline (day 1), on day 3 of
both treatment phases, and weekly thereafter until the end of the
study included sK, serum chemistry (including serum creatinine and
estimated glomerular ﬁltration rate), aldosterone, and PRA. Sitting
BP was measured in triplicate at baseline, day 3 of each phase, and
weekly thereafter. Urine samples were collected for ACR at baseline
and every 4 weeks from the start of the study until the end of the
study. Aldosterone and PRA were measured by chemiluminescent
immunoassay.45,46 Intra-assay coefﬁcient of variation was 2.5% to
5.4% and 4.6% to 10%, and the interassay coefﬁcient of variation
was 3.8% to 15.7% and 5.6% to 7.6% for aldosterone and PRA
assays, respectively.
Statistical methods
Initial treatment phase. To evaluate the mean changes in
serum aldosterone, PRA, SBP, and DBP in the initial treatment
phase, data from all 243 enrolled patients were analyzed. An MMRM
using restricted likelihood estimation was respectively ﬁtted to
weekly change from baseline measurements based on each central
laboratory parameter (or clinical assessment) as the response vari-
ables by adjustment for the corresponding baseline value, visit,
baseline HK severity, and interaction of visit by baseline HK severity.
The dependency in repeated observations was modeled using an
unstructured covariance ﬁtted to within-subject correlations. The
mean  SE for all measures at speciﬁed time points (i.e., baseline
and weeks 1–4) were based on observed cases and plotted.
Because ACRwas only collected at monthly visits, themean change
in ACR from baseline to week 4 by baseline HK severity was based on
analysis of covariance by adjusting for the baseline ACR value.
To exclude other possible drug effects on serum aldosterone, a
sensitivity analysis was performed on serum aldosterone change by
using the same model described previously, excluding any aldoste-
rone antagonist use and any modiﬁcations of RAASi medications,
non-RAASi, nondiuretic antihypertensive medications, or diuretics.
In addition, to further conﬁrm the serum aldosterone change
pattern and estimate the other covariate effects, an extendedKidney International (2016) 90, 696–704multivariate MMRM was conducted. Along with adjustments in the
original MMRM, this extended model also included pooled age
group (65 years of age or older vs. younger than 65 years of age), sex,
CKD stages by estimated glomerular ﬁltration rate, presence or
absence of type 2 diabetes mellitus, and history of heart failure.
In order to explore whether serum aldosterone changes are asso-
ciatedwith patterned increased or decreased potassium, PRA, SBP, and
DBP at baseline, day 3 (early effect), and week 4 (end of the initial
treatment phase), a 1-way analysis of variance was used for baseline or
change from baseline comparisons of central laboratory measures and
BPswhen the patientswere subdivided into aldosterone tertiles; tertiles
were deﬁned by baseline values and the change in aldosterone values at
day 3 and week 4. Values are expressed as mean  SD.
Randomized withdrawal phase. To investigate the mean
changes in serum aldosterone, PRA, SBP, and DBP in the 8-week
randomized withdrawal treatment phase, data from the 107 ran-
domized patients were analyzed. An MMRM was ﬁtted to weekly
change from the start of the randomized withdrawal phase mea-
surements based on the central laboratory as the response variables
by adjustment for the start value, visit, treatment (patiromer vs.
placebo), and interaction of visit by treatment. The dependency in
repeated observations was modeled using an unstructured covari-
ance ﬁtted to within-patient errors. The mean and SE for all mea-
sures at the speciﬁed time points (e.g., start value, weeks 4 and 8
during the randomized withdrawal phase) were based on observed
cases. The ACR was analyzed by using the same methods described
in the initial treatment phase.
Descriptive statistics for baseline demographic and characteristics
were summarized as mean  SD for continuous variables or pro-
portions for categorical variables. All analyses were performed using
SAS version 9.4 (SAS Institute, Cary, North Carolina), with statistical
signiﬁcance set at P < 0.05.DISCLOSURE
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